CEL-SCI Reports Monthly Patient Enrollment in February for Its Phase 3 Head and Neck Cancer Trial
CEL-SCI Corporation ("CEL SCI" or the "Company") today announced that during the month of February it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment for the trial is now 724 as of February 29, 2016 in the world's largest Phase 3 study in head and neck cancer.
View full press release